Literature DB >> 19462533

Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein.

Jinwoo Ahn1, Masha V Poyurovsky, Nicole Baptiste, Rachel Beckerman, Christine Cain, Melissa Mattia, Kristine McKinney, Jianmin Zhou, Andrew Zupnick, Vanesa Gottifredi, Carol Prives.   

Abstract

Both sequence-specific DNA binding and exonuclease activities have been mapped to the central conserved core domain of p53. To gain more information about these two activities a series of mutants were generated that changed core domain histidine residues. Of these mutants, only one, H115N p53, showed markedly reduced exonuclease activity (ca. 15% of wild-type). Surprisingly, purified H115N p53 protein was found to be significantly more potent than wild-type p53 in binding to DNA by several criteria including gel mobility shift assay, filter binding and DNase I footprinting. Interestingly as well, non-specific DNA binding by the core domain of H115N p53 is superior to that of wild-type p53. To study H115N p53 in vivo, clones of H1299 cells expressing tetracycline regulated wild-type or H115N p53 were generated. H115N was both more potent than wild-type p53 in inducing p53 target genes such as p21 and PIG3 and was also more effective in arresting cells in G1. Unexpectedly, in contrast to wild-type p53, H115N p53 was markedly impaired in causing apoptosis when cells were subjected to DNA damage. Our results indicate that the exonuclease activity and transcriptional activation functions of p53 can be separated. They also extend previous findings showing that cell cycle arrest and apoptosis are separable functions of p53. Finally, these experiments confirm that DNA binding and xonuclease activities are distinct features of the p53 core domain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19462533      PMCID: PMC2898518          DOI: 10.4161/cc.8.10.8548

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  74 in total

1.  Interaction between replication protein A and p53 is disrupted after UV damage in a DNA repair-dependent manner.

Authors:  N A Abramova; J Russell; M Botchan; R Li
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

2.  DNA polymerase beta: structure-fidelity relationship from Pre-steady-state kinetic analyses of all possible correct and incorrect base pairs for wild type and R283A mutant.

Authors:  J Ahn; B G Werneburg; M D Tsai
Journal:  Biochemistry       Date:  1997-02-04       Impact factor: 3.162

3.  A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis.

Authors:  P Friedlander; Y Haupt; C Prives; M Oren
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

Review 4.  p53: puzzle and paradigm.

Authors:  L J Ko; C Prives
Journal:  Genes Dev       Date:  1996-05-01       Impact factor: 11.361

5.  Human p53 binds Holliday junctions strongly and facilitates their cleavage.

Authors:  S Lee; L Cavallo; J Griffith
Journal:  J Biol Chem       Date:  1997-03-14       Impact factor: 5.157

6.  p53 Protein exhibits 3'-to-5' exonuclease activity.

Authors:  T Mummenbrauer; F Janus; B Müller; L Wiesmüller; W Deppert; F Grosse
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

7.  Genetic determinants of p53-induced apoptosis and growth arrest.

Authors:  K Polyak; T Waldman; T C He; K W Kinzler; B Vogelstein
Journal:  Genes Dev       Date:  1996-08-01       Impact factor: 11.361

8.  Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function.

Authors:  R L Ludwig; S Bates; K H Vousden
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

9.  p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells.

Authors:  X Chen; L J Ko; L Jayaraman; C Prives
Journal:  Genes Dev       Date:  1996-10-01       Impact factor: 11.361

10.  Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.

Authors:  S Rowan; R L Ludwig; Y Haupt; S Bates; X Lu; M Oren; K H Vousden
Journal:  EMBO J       Date:  1996-02-15       Impact factor: 11.598

View more
  10 in total

1.  The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis.

Authors:  Siddharth Singh; Manoj Kumar; Sanjeev Kumar; Shrinka Sen; Pawan Upadhyay; Sayan Bhattacharjee; Naveen M; Vivek Singh Tomar; Siddhartha Roy; Amit Dutt; Tapas K Kundu
Journal:  J Biol Chem       Date:  2019-07-31       Impact factor: 5.157

2.  Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276).

Authors:  Youfeng Yang; Cathy D Vocke; Christopher J Ricketts; Darmood Wei; Hesed M Padilla-Nash; Martin Lang; Carole Sourbier; J Keith Killian; Shawna L Boyle; Robert Worrell; Paul S Meltzer; Thomas Ried; Maria J Merino; Adam R Metwalli; W Marston Linehan
Journal:  Genes Chromosomes Cancer       Date:  2017-07-24       Impact factor: 5.006

3.  DNA damage tolerance pathway involving DNA polymerase ι and the tumor suppressor p53 regulates DNA replication fork progression.

Authors:  Stephanie Hampp; Tina Kiessling; Kerstin Buechle; Sabrina F Mansilla; Jürgen Thomale; Melanie Rall; Jinwoo Ahn; Helmut Pospiech; Vanesa Gottifredi; Lisa Wiesmüller
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-12       Impact factor: 11.205

4.  Synthetic lethality between TP53 and ENDOD1.

Authors:  Zizhi Tang; Ming Zeng; Xiaojun Wang; Chang Guo; Peng Yue; Xiaohu Zhang; Huiqiang Lou; Jun Chen; Dezhi Mu; Daochun Kong; Antony M Carr; Cong Liu
Journal:  Nat Commun       Date:  2022-05-23       Impact factor: 17.694

Review 5.  Awakening guardian angels: drugging the p53 pathway.

Authors:  Christopher J Brown; Sonia Lain; Chandra S Verma; Alan R Fersht; David P Lane
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

6.  Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.

Authors:  Jackson R Taylor; Brian D Lehmann; William H Chappell; Stephen L Abrams; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2011-08

Review 7.  The Tip of an Iceberg: Replication-Associated Functions of the Tumor Suppressor p53.

Authors:  Vanesa Gottifredi; Lisa Wiesmüller
Journal:  Cancers (Basel)       Date:  2018-07-28       Impact factor: 6.639

8.  p53 isoforms differentially impact on the POLι dependent DNA damage tolerance pathway.

Authors:  Lisa Wiesmüller; Stephanie Biber; Yitian Guo; Melanie Rall-Scharpf; Jean-Christophe Bourdon
Journal:  Cell Death Dis       Date:  2021-10-13       Impact factor: 8.469

Review 9.  Exonucleases: Degrading DNA to Deal with Genome Damage, Cell Death, Inflammation and Cancer.

Authors:  Joan Manils; Laura Marruecos; Concepció Soler
Journal:  Cells       Date:  2022-07-09       Impact factor: 7.666

Review 10.  How the Other Half Lives: What p53 Does When It Is Not Being a Transcription Factor.

Authors:  Teresa Ho; Ban Xiong Tan; David Lane
Journal:  Int J Mol Sci       Date:  2019-12-18       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.